Physician profile
Kaushik Chatterjee
NPI 1538464060
$1,751.27
in general payments reported to CMS, 2019-2025
27 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $51.48 · 2021: $298 · 2022: $656 · 2023: $309 · 2024: $89.43 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.77 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $442.87 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Novo Nordisk INC | $193.49 | 2019-2022 | |
| Lilly USA, LLC | $169.93 | 2019-2023 | Mounjaro |
| Abbott Laboratories | $114.76 | 2021-2025 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $96.61 | 2019 | |
| Tandem Diabetes Care, INC. | $73.09 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $69.32 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $54.52 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $52.33 | 2022 | |
| Antares Pharma, INC. | $49.69 | 2022 | |
| Corcept Therapeutics | $45.61 | 2021-2022 | |
| Amgen INC. | $38.74 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $37.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.66 | 2022 | |
| Lifescan, INC. | $31.33 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.00 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $28.14 | 2023 | Imcivree |
| Radius Health, INC. | $28.01 | 2022-2024 | Tymlos |
| Horizon Therapeutics Plc | $21.57 | 2023 | Tepezza |
| Janssen Biotech, INC. | $20.89 | 2020 | |
| Amryt Pharma Holdings LTD | $20.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.33 | 2022 | |
| Mannkind Corporation | $17.33 | 2022 | |
| Recordati_rare_diseases_inc. | $16.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.37 | 2020 | |
| Insulet Corporation | $15.15 | 2023 | Omnipod |
| Pfizer INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaushik Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.